Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit
a clinical-stage, cutting edge quality altering organization zeroed in on treatments that outfit designated quality incorporation to treat or fix genuine sicknesses, declared today that individuals from the supervisory crew will take part in a fireside talk at the Jefferies Gene Therapy/Editing Summit on Thursday, Oct. 28, 2021, at 4:30 p.m. ET.
The fireside talk will be webcast live from Graphite Bio’s site at www.graphitebio.com in the Investors area. A replay of the webcast will be filed and accessible for one month following the occasion.
About Graphite Bio
Graphite Bio is a clinical-stage, cutting edge quality altering organization tackling high effectiveness designated quality incorporation to foster another class of treatments to possibly fix a wide scope of genuine and dangerous infections. Graphite Bio is spearheading an accuracy quality altering approach that could empower an assortment of uses to change human wellbeing through its capability to accomplish one of medication’s most tricky objectives: to definitively “find and supplant” any quality in the genome. Graphite Bio’s foundation permits it to definitively address changes, supplant whole illness causing qualities with ordinary qualities or supplement new qualities into foreordained, safe areas. The organization was helped to establish by scholarly pioneers in the fields of quality altering and quality treatment, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
